Kornimate/medical-research-clean huggingface dataset:
abdominal breathing on improving of sleep quality and physiological index among patients with insomnia

Conditions: Insomnia

Summary: the research topic is to explore the effectiveness of abdominal breathing on improving of sleep quality and physiological index (heart rate, respiration rate and blood pressure) among patients with insomnia. this study method adopts the research design of experimental randomized controlled trials. the persons receiving the intervention of abdominal breathing training are in the experimental group, while those who do not receive it are in the control group.

sleep problem is very common symptom problems, so often rely on sedative-hypnotics drugs. however, long-term dependence on drugs may bring serious side effects. therefore, the research topic is to explore the effectiveness of abdominal breathing on improving of sleep quality and physiological index (heart rate, respiration rate and blood pressure) among patients with insomnia. this study method adopts the research design of experimental randomized controlled trials. the persons receiving the intervention of abdominal breathing training are in the experimental group, while those who do not receive it are in the control group. the research is conducted with a and b groups. group a is for those who take sedative and sleeping medicine, and group b is for those who do not take sedative and sleeping medicine. both groups a and b have experimental group and control group. the effectiveness assessment will use the pittsburgh quality sleep index (psqi) and vital signs (heart rate, breathing and blood pressure). these assessments need to complete by both the experimental group and control group. this study uses the pre-test before the implementation of abdominal breathing training, and uses the post-test at week 4 and week 8 the end of abdominal breathing training. the experimental group will receive the abdominal breathing training for a total of 8 weeks. abdominal breathing training is carry out in the sleep center of hospital (once every 1 week, and 15 minutes every time). when the persons are at home, they will receive self-training using the abdominal breathing training video (every day 10 minutes, can include every time during the day). moreover, the persons need to complete the "abdominal breathing training log". hopefully, this study may develop that does not use drugs, but improves sleep quality and physiological index through abdominal breathing.

Eligibility criteria:
inclusion criteria: * those with a total score greater than 5 points on the pittsburgh sleep product quality table have been diagnosed with insomnia based on the taiwan psychiatric association (2014) dsm-5 psychiatric disorder diagnosis and statistics, who have agreed to participate in this study and have completed a written consent form. exclusion criteria: * patients with copd

Keywords: abdominal breathing quality of sleep physiological index effectiveness
a study to evaluate whether correction of anemia using recombinant human erythropoietin reduces the progression of atherosclerosis and cardiac hypertrophy in pre-dialysis chronic kidney disease patients

Conditions: Chronic Disease; Kidney Diseases; Cardiovascular Diseases

Summary: the primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease


Eligibility criteria:
inclusion criteria: * patients with chronic renal failure with serum creatinine between 150umol/l and 800umol/l and at the same time hb * patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months * patients below the age of 75 exclusion criteria: * patients with valvular heart disease/congenital heart disease * patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery * patients with history of heart failure * patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months * patients with thalassemic trait or haemoglobinopathies * patients with underlying haematological malignancies * patients with active bleeding * patients with uncorrected iron or other vitamins deficiencies * patients with poor general condition

Keywords: chronic kidney disease cardiovascular disease
blinatumomab in combination with amg 404 for the treatment of adults with relapsed or refractory b cell precursor all

Conditions: Acute Lymphoblastic Leukemia

Summary: the primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and amg 404 in combination in adults with r/r b-all and to estimate the maximum tolerated dose (mtd) and recommended phase 2 dose (rp2d) of amg 404 when combined with continuous intravenous infusion (civ) blinatumomab.


Eligibility criteria:
inclusion criteria * age ≥ 18 years at enrollment. * greater than or equal to 5% blasts in the bone marrow. * eastern cooperative oncology group performance status (ecog ps) ≤ 2. * negative pregnancy test in women of childbearing potential. exclusion criteria * cancer chemotherapy (radiotherapy, chemotherapy, antibody therapy, molecular targeted therapy) within 14 days prior to study day 1. * known hypersensitivity to blinatumomab or amg 404 or to any component of the product formulation.

Keywords: blinatumomab amg 404 leukemia
identifying and measuring depression in older cancer patients

Conditions: Older Cancer Patients

Summary: the purpose of this study is to develop an accurate and useful way of measuring older patients' moods and reactions to the combined issue of cancer treatment and aging. also, the purpose of this study is to test a new self-report measure of depressive symptoms tailored to the needs of older adults with cancer. findings from this research will help us develop improved methods of diagnosis and treatment.


Eligibility criteria:
inclusion criteria: for patients in phases 1- 3: * current or previous cancer diagnosis and treatment (any site and any stage) * all phases 1,2,3- 70 years of age or older * for phase 1b only; 50 participants ages 50-69 will also be recruited * for phase 2 only: as per medical record or self report, history of depression, dysthymia, or adjustment disorder with depressed mood * for phase 3 depressive subset: as per medical record or self report, a history of depressive symptoms such as * adjustment disorder with depressed mood * adjustment disorder with mixed depressed mood and anxiety * mood disorder (i.e., due to general medical condition, not otherwise specified) * depressive disorder (i.e., major depressive disorder (mdd) single episode, mdd recurrent, depressive disorder not otherwise specified, dysthymia) * in the judgment of the consenting professional able to communicate, comprehend, and complete questionnaires in english exclusion criteria: for patients in parts 1- 3: * in the judgment of the consenting professional and/or as per medical record, severe psychopathology or cognitive impairment likely to interfere with the participation or completion of the protocol or ability to provide meaningful information. * for phase 1\&2 only: score of \> 11 on the blessed orientation-memory-concentration scale (bomc) * for part 2 only: as per medical record or self report, a diagnosis of a schizophrenia spectrum disorder, current substance use disorder, bipolar disorder or schizotypal personality disorder. schizophrenia spectrum disorders include schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, attenuated psychotic disorder, and adjustment disorder (except for adjustment disorder with depressed mood).

Keywords: depression 14-101
study of the prognostic role of gene polymorphism in the development of b-cell leukemias and lymphomas in children of kazakh nationality

Conditions: B Cell Leukemia; Lymphoma

Summary: to search for a genetic marker of b-cell leukemias and lymphomas in children of kazakh nationality, a single nucleotide polymorphism (snp) analysis of dna obtained from the peripheral blood of patients with b-cell leukemias and lymphomas in children of kazakh nationality and normal control will be performed.


Eligibility criteria:
inclusion criteria: * ethnicity - kazakhs in at least three generations * active disease or a history of b-line all or b-nhl, established on the basis of morphological, cytochemical, immunophenotypic or immunohistochemical research methods with confirmation of the fact of the disease in medical documentation * signed voluntary informed consent of the legal representative to participate in the project exclusion criteria: * children suffering from other types of malignant neoplasms * children with b-linear leukemia and lymphomas with concomitant specified genetic and chromosomal diseases * children of non-kazakh nationality * absence of signed informed consent or informed refusal of the legal representative to participate in the study before starting therapy

Keywords: snp
platelet-rich protein and the endometrium

Conditions: Infertility

Summary: platelet-rich plasma (prp) may promote the endometrial growth and improve pregnancy outcome of patients with thin endometrium undergoing art treatments.


Eligibility criteria:
inclusion criteria: * women undergoing a frozen thawed embryo transfer cycle with poor endometrial response to estrogen (\< 7 mm) after at least two standard preparation protocols, of which one was canceled due to thin endometrium exclusion criteria: * none
low dose apomorphine and parkinsonism

Conditions: Parkinson's Disease

Summary: the purpose of this study is to determine if low doses of apomorphine worsen the motor symptoms of parkinson's disease.

the goal of the study is to learn why some people with parkinson's disease (pd) get worse right after taking pd medication such as carbidopa/levodopa or as the medication is wearing off. in this study scientists will determine if apomorphine, a drug used to treat symptoms of pd, will worsen the motor symptoms of people with pd when low doses of the drug are given as a continuous subcutaneous infusion. a continuous subcutaneous infusion means the drug is administered continuously through a small needle placed under the skin. apomorphine, a pd drug that works similar to carbidopa/levodopa, will be used in this study because it is faster-acting and has a more brief effect than carbidopa/levodopa. after the initial screening, participants will enter a 3-day treatment phase during which they will receive in random order low dose apomorphine, high dose apomorphine, or placebo (inactive substance). all participants will receive the study drug for 2 of the days at 2 different doses (low and high) and a placebo for 1 day. during the 3 days participants will provide blood samples and have their hearts monitored. parkinsonism will be monitored each day by speed of finger tapping, foot tapping and walking as well as tremor and dyskinesia scores. duration of the study for participants is approximately 4 to 5 days including 1-2 outpatient visits and a 3-day inpatient hospital stay.

Eligibility criteria:
inclusion criteria: * have idiopathic parkinson's disease treated with levodopa and experiencing motor fluctuations * response to levodopa had to be documented by a 10 percent increase in finger or foot tapping speed exclusion criteria: * clinically significant cardiovascular, cerebrovascular, hepatic and renal diseases * psychosis * allergy to apomorphine or 5ht3 inhibitors * prolonged qt interval * pregnancy/breast-feeding * hemodynamic instability * severe nausea * alcohol/drug abuse * other unstable medical conditions

Keywords: parkinson's disease pd apomorphine
smart diabetic foot care application

Conditions: Diabetic Foot

Summary: this study developed an app for the guidance of home-based diabetic foot care to explore its impact on patients' foot assessment awareness and self-care behavior after using this app. the study also assessed the app's effectiveness in cultivating behavioral habits that are effective in managing diabetes.

diabetes is a common chronic metabolic disease worldwide. approximately 50% to 60% of ulcers caused by diabetes become infected, and moderate to severe infections can lead to lower limb amputation. among amputees, the five-year mortality rate exceeds 70%.smart devices (mobile phones, computers, etc.) are indispensable necessities to modern lives. downloadable mobile health applications (mhealth apps) on smartphones are widely used in medical care . the use of these apps on smartphones has created a new field in the health industry known as mobile health

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of type 2 diabetes . 2. aged between 20 and 80 years. 3. able to use mobile apps or tablets for health management . exclusion criteria: 1. patients who were unconscious, had delirium, were bedridden, had cognitive impairment, or were unable to perform daily self-care. 2. patients who refused to participate.
integrated intervention for substance abusers with depressive disorders

Conditions: Substance-Related Disorders; Depressive Disorder

Summary: this study is a randomized clinical trial comparing outcomes of integrated cognitive behavioral treatment plus standard medications for veterans with both substance use disorders, depressive disorders versus the most commonly administered form of therapy for substance use disorders and depression, twelve step facilitation (aa/na model) group treatment plus medications.

this study is a randomized clinical trial comparing outcomes of integrated cognitive behavioral treatment plus standard medications for veterans with both substance use disorders, depressive disorders versus the most commonly administered form of therapy for substance use disorders and depression, twelve step facilitation (aa/na model) group treatment plus medications. follow-up assessments were conducted at quarterly intervals for one year following treatment.

Eligibility criteria:
inclusion criteria: veterans age 18 and older with alcohol, cannabinol, and/or stimulant dependence and independent mood disorders will be included. exclusion criteria: psychotic disorders

Keywords: mood disorders substance-related disorders
association between systemic exposure of atorvastatin and metabolites and atorvastatin-induced myotoxicity

Conditions: Myopathy

Summary: the aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared to healthy controls.

a 24 hour pharmacokinetic investigation of atorvastatin and metabolites will be performed in 15 patients with a history of atorvastatin -induced myotoxicity. the possible link to relevant mutations in slco1b1, cyp3a5 and mdr1 will be also be investigated

Eligibility criteria:
inclusion criteria: * above 18 years * previous history of atorvastatin-associated myotoxicity exclusion criteria: * current treatment with drugs or herbal remedies with known pharmacokinetic interaction potential with atorvastatin * previous ck levels above ten times the upper limit of normal range * pregnancy and persistent muscular complaints after a four week wash-out period of statin treatment
physiotherapy and therapeutic exercise program in graft-versus-host disease (gvhd)

Conditions: GVHD,Acute; GVHD, Chronic

Summary: range of motion, antropometric measurements, quality of life questionnaire and 2 minutes walk test will be implemented as an initial assessment. physical exercise program will take 2 sessions a week for six months, and several follow-ups: before, during and after treatment.


Eligibility criteria:
inclusion criteria: * allogenic transplantation patients with graft versus host disease exclusion criteria: * cognitive impairment * physical limitation from other pathologies
flexible colonoscope assisted hybrid transanal total mesorectal resection (tatme)

Conditions: Rectal Cancer

Summary: the investigators propose to use flexible endoscopy combined with transanal total mesorectal resection to further reduce anal injury.

endoscopic technique has become an indispensable part of natural orifice transluminal endoscopic surgery (notes). however, the upper gastrointestinal tract is easy to cause severe leakage complications, which mainly limits the application of endoscopy in rectum. herein, investigators propose purse suture closing distal rectum and full-layer incision of the rectal wall using flexible endoscopic from anal to assist in hybrid transanal total mesorectal resection (tatme).further reduce the damage of anus caused by tatme.

Eligibility criteria:
inclusion criteria: 1. age between 18 and 80 years old 2. confirmed rectal adenocarcinoma cancer pathologically 3. tumor location ≦ 12 cm from the anal margin 4. willing and able to provide written informed consent for participation in this study exclusion criteria: 1. distant metastasis before surgery 2. more than one colorectal tumor at diagnosis 3. familial adenomatous polyposis 4. recurrent rectal cancer 5. undergo transanal minimally invasive surgery 6. undergo palliative treatment 7. undergo emergency surgery
a study of tyra-300 in children with achondroplasia: beach301

Conditions: Achondroplasia

Summary: the purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of tyra-300 in children with achondroplasia with open growth plates.

this is a phase 2, multicenter, open-label, dose-escalation study to determine the safety, tolerability, and identify potentially effective dose(s) of tyra-300, a fibroblast growth factor receptor (fgfr)-3 selective tyrosine kinase inhibitor, in children 3 to 10 years of age with achondroplasia with open growth plates that will examine three cohorts of children: the sentinel safety cohort, cohort 1, and cohort 2.

Eligibility criteria:
inclusion criteria: * aged 3 to 10 years old (inclusive) at the time of consent. * informed consent provided by parent(s) or legal guardian(s). as study participants are less than 18 years old, participants are willing and able to provide written assent (where applicable and required). * molecular diagnosis of achondroplasia (fgfr3 g380r). * radiographically confirmed open growth plates at screening, as determined by bone age x-ray. * able to stand and ambulate independently. * able to take oral medication. * sentinel safety cohort only: aged 5 to 10 years old (inclusive). * cohort 1 only: aged 3 to 10 years old (inclusive) and are naive to prior growth accelerating therapy. * cohort 2 only: aged 3 to 10 years old (inclusive) and have received prior growth accelerating therapy. exclusion criteria: * presence or history of any concurrent disease or condition that would interfere with study participation, safety evaluations, or any uncontrolled or untreated condition that could impact pediatric growth. * diagnosis of endocrine condition that alters calcium/phosphate homeostasis. * prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study. * taking medications that are strong inhibitors or inducers of cytochrome p450 (cyp) 3a4. * history or current evidence of corneal or retinal disorder/keratopathy. * presence of guided growth hardware/8 plates. planned or anticipated orthopedic surgeries.
nkg2d car-nk & ovarian cancer

Conditions: Ovarian Cancer

Summary: this trial will explore the maximum tolerated dose （mtd）of nkg2d car-nk cells in the treatment of platinum-resistant, relapsed epithelial ovarian cancer in a dose-escalation manner, and observe the clinical safety and efficacy.


Eligibility criteria:
inclusion criteria: 1. age 18 years and older 2. histologically or cytologically confirmed diagnosis of epithelial ovarian cancer 3. documented platinum resistant epithelial ovarian cancer with at least 1 measurable lesion 4. ecog performance status of 0-2 5. adequate organ function defined as: anc≥1.5×109/l, plt≥75×109/l, tbil≤1.5×uln, ast≤2.5×uln, alt≤2.5×uln, cr≤1.5×uln 6. negative urine or serum pregnancy test within 7 days prior to treatment for women of childbearing age 7. life expectancy ≥ 12 weeks from the time of enrollment 8. all patients must have the ability to understand and willingness to sign a written informed consent form (icf). exclusion criteria: 1. patients with history of other active malignancy within 1 year prior to enrollment; 2. patients with central nervous system (cns) metastases. history of any cns disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, any autoimmune disease with cns involvement, posterior reversible encephalopathy syndrome, or cerebral edema; 3. patients with ongoing uncontrolled serious infection, clinically significant cardiac disease (i.e., symptomatic congestive heart failure, myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, uncontrolled cardiac arrhythmia), poorly controlled pulmonary disease (no clinically significant pleural effusion), or psychiatric illness/social situations that would limit compliance with study requirements within 12 months prior to enrollment; 4. patients with immunologic deficiency or autoimmune diseases; 5. known human immunodeficiency virus (hiv) seropositivity or active hepatitis b or c infection. a history of hepatitis b or c is permitted if the viral load is undetectable by quantitative assay; 6. patients who are breastfeeding or pregnant; 7. patients, who in the opinion of the investigator, may not be able to comply with the monitoring requirements of the study; 8. patients participated in another investigation treatment study 4 weeks prior to enrollment.

Keywords: car-nk
effect of eye make up on ocular surface

Conditions: Meibomian Gland Dysfunction

Summary: the aim of this study is to compare the degree of tear film instability and severity of meibomian gland loss between subjects who use eyeliner, mascara, a combination of both and those who do not use eyeliner.


Eligibility criteria:
inclusion criteria: to use eyeliner/mascara or combined for at least 3 days for 6 months for study groups no routine eye make up use for the cıontrol group - exclusion criteria: * any systemic or ocular disease taht can affect ocular surface

Keywords: meibomian, eyeliner
anesthetic advantages of dexmedetomidine for hypotensive anesthesia

Conditions: Anesthesia; Hypotension

Summary: the aim of this study was to evaluate the positive anesthetic properties such as reduce intraoperative analgesic requirement, time to extubation and recovery, and early postoperative pain of dexmedetomidine used as a hypotensive agent compared with nitroglycerin.

the subject included the healthy patients who underwent orthognathic surgery and gave written the informed consent. the sample size was calculate from the amount of fentanyl use in orthognathic surgical case and difference more 30% was significant. randomization was done by random number table to 2 groups. both groups received standardized controlled hypotensive anesthesia and surgery. d group used dexmedetomidine as the hypotensive drug and n group use nitroglycerin. the main outcome were the amount of fentanyl use, time to eye opening, follow simple command, extubation, early postoperative pain, and early postoperative amount of pain killer. all recorded by anesthesiologist on data sheet. compare statistical analysis used compare mean by unpaired student t test.

Eligibility criteria:
inclusion criteria: * patients who undergo bimaxillary surgery physical status i according to the classification of the american society of anesthesiologist age 18-45 years exclusion criteria: * systemic diseases not given informed consent

Keywords: dexmedetomidine controlled hypotensive anesthesia